Evidence map›Paper›PMID 42660898›Full record

ArticleNature communications2026

Engineering viral protease-operated nanobodies for programmable and orthogonal control of protein function.

Mingguang Cui, Xiaoxuan Liu, Tien-Hung Lan, Tianlu Wang, Tatsuki Nonomura, Brendan McKee, Rui Wang, Yun Huang, Yubin Zhou

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mingguang Cui *Center for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, TX, USA.ORCID 0000-0002-2788-5166
Xiaoxuan Liu *Center for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, TX, USA.
Tien-Hung Lan *Center for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, TX, USA.ORCID 0009-0009-4080-2255
Tianlu WangCenter for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, TX, USA.
Tatsuki NonomuraCenter for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, TX, USA.
Brendan McKeeCenter for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, TX, USA.ORCID 0009-0004-0302-0530
Rui WangCenter for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, TX, USA.
Yun HuangCenter for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, USA. yun.huang@tamu.edu.ORCID 0000-0001-5950-9168
Yubin ZhouCenter for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, TX, USA. yubinzhou@tamu.edu.ORCID 0000-0001-7962-0517

Funding

Engineering Smart Antibody-like Protein Scaffolds with precision switchesR01GM144986 · NIGMS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ZHOU, YUBIN · 2022 to 2025
$1.3M
Molecular control of calcium signaling at membrane contact sitesR35GM163674 · NIGMS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Yubin Zhou · 2026 to 2026
$419k
Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RP250468NIGMS NIH HHS R01 GM144986NIGMS NIH HHS R35 GM163674U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM163674, R01GM144986Welch Foundation A-2310-2060402
6 · The paper itself

Abstract

Precise control of protein function in living cells is essential for engineering programmable biological systems and therapeutic applications. However, most current strategies act indirectly by altering protein stability, localization, or proximity rather than directly modulating binding activity. Here we present VIPbodies, nanobodies engineered with self-cleaving viral proteases that convert protease inhibition into drug-dependent antigen recognition. Using anti-mCherry nanobodies as prototypes, we create variants responsive to orthogonal viral protease-inhibitor pairs and extend the design to diverse nanobody scaffolds. Each VIPbody functions independently within the same cell, enabling multiplexed regulation of distinct targets. When incorporated into transcriptional circuits, VIPbodies mediate drug-tunable gene expression and execute all six canonical Boolean logic operations, providing a compact framework for programmable cellular computation. Beyond gene regulation, VIPbody circuits mediate bidirectional control of pyroptosis and selectively activate apoptotic or pyroptotic programs via caspase coupling, thereby enabling chemogenetic control of protein function and cell fate.

Indexed as

Protein EngineeringSingle-Domain AntibodiesViral ProteasesAnimalsChemogeneticsHEK293 CellsHumansLuminescent ProteinsProtease InhibitorsLuminescent ProteinsProtease InhibitorsSingle-Domain AntibodiesViral Proteases

Identifiers

PMID42660898
PMCPMC13522513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.